FDA approves biosim to Regeneron Eylea, Evotec exits gene therapy, J&J reports deaths in radioligand trial [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — FDA approves first interchangeable biosims to Regeneron Eylea
The bad — Evotec exits gene therapy
The ugly — J&J reports deaths in early-stage radioligand trial